Polar Capital’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Polar Capital’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$117M	Sell	1,501,008 -236,698	-14%	-$16.3M	0.87%	28
2020 Q2	$96.6M	Sell	1,737,706 -938,786	-35%	-$40.2M	0.83%	27
2020 Q1	$79.3M	Buy	2,676,492 +517,236	+24%	+$17.5M	0.85%	23
2019 Q4	$78.2M	Sell	2,159,256 -98,529	-4%	-$3.02M	0.68%	29
2019 Q3	$61.5M	Buy	2,257,785 +168,699	+8%	+$4.36M	0.55%	52
2019 Q2	$50.3M	Buy	2,089,086 +143,248	+7%	+$3.63M	0.44%	75
2019 Q1	$51.4M	Buy	+1,945,838	New	+$46.1M	0.48%	70

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Polar Capital's HZNP Position: Q3 2020 in Review

Polar Capital reduced its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 14% in Q3 2020, selling an estimated $16.3M and leaving 1,501,008 shares worth $117M. The position accounts for 0.87% of the portfolio, ranked #28.

Polar Capital first reported a position in HZNP in Q1 2019 and has held it in 7 quarters since. 433 funds tracked by Wall St. Rank hold HZNP as of Q3 2020.

Polar Capital held 1,501,008 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $117M as of Q3 2020.
Polar Capital sold 236,698 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2020, an estimated $16.3M.
Horizon Therapeutics Public Limited Company Ordinary Shares made up 0.87% of Polar Capital's portfolio in Q3 2020, its #28 holding.
Polar Capital first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2019 and has held it in 7 quarters since.
433 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2020.

Based on Polar Capital's 13F filing for Q3 2020, filed 16 Nov 2020.